단계 미표기모집 중
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)
연구 개요
This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD). The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF). During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration. The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.
- 스폰서
- 리드: 다케다
- 적응증
- Von Willebrand Disease (vWD)
- 중재
- vonicog alfa (rVWF)
- 목표 등록
- 13명
- 시작일
- 2026-02-19
- 완료(예정)
- 2031-05-30
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.